These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

330 related items for PubMed ID: 30535785

  • 1. Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study.
    Lee DR, Lee J.
    Osteoporos Int; 2019 Mar; 30(3):659-666. PubMed ID: 30535785
    [Abstract] [Full Text] [Related]

  • 2. The effectiveness of ibandronate in reducing the risk of nonvertebral fractures in women with osteoporosis: systematic review and meta-analysis of observational studies.
    Alves C, Mendes D, Penedones A, Oliveira T, Donato A, Batel-Marques F.
    Int J Clin Pharm; 2024 Apr; 46(2):357-367. PubMed ID: 38112890
    [Abstract] [Full Text] [Related]

  • 3. Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density.
    Naylor KE, Bradburn M, Paggiosi MA, Gossiel F, Peel NFA, McCloskey EV, Walsh JS, Eastell R.
    Osteoporos Int; 2018 Jun; 29(6):1407-1417. PubMed ID: 29525970
    [Abstract] [Full Text] [Related]

  • 4. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg.
    Epstein S, Jeglitsch M, McCloskey E.
    Curr Med Res Opin; 2009 Dec; 25(12):2951-60. PubMed ID: 19835464
    [Abstract] [Full Text] [Related]

  • 5. Comparison of monthly ibandronate versus weekly risedronate in preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women.
    Chung YS, Lim SK, Chung HY, Lee IK, Park IH, Kim GS, Min YK, Kang MI, Chung DJ, Kim YK, Choi WH, Shong MH, Park JH, Byun DW, Yoon HK, Shin CS, Lee YS, Kwon NH.
    Calcif Tissue Int; 2009 Nov; 85(5):389-97. PubMed ID: 19816648
    [Abstract] [Full Text] [Related]

  • 6. Anti-fracture Efficacy of Monthly Risedronate Compared with That of Weekly Risedronate in Postmenopausal Korean Women with Osteoporosis: A Nationwide Cohort Study.
    Cho YH, Bae KH, Lee DR, Lee J.
    Korean J Fam Med; 2020 Sep; 41(5):339-345. PubMed ID: 32447881
    [Abstract] [Full Text] [Related]

  • 7. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
    Abelson A, Ringe JD, Gold DT, Lange JL, Thomas T.
    Osteoporos Int; 2010 Jun; 21(6):1021-9. PubMed ID: 19722103
    [Abstract] [Full Text] [Related]

  • 8. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M, Viapiana O, Gatti D, Adami S.
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [Abstract] [Full Text] [Related]

  • 9. Analysis of the comparative effectiveness of 3 oral bisphosphonates in a large managed care organization: adherence, fracture rates, and all-cause cost.
    Martin KE, Yu J, Campbell HE, Abarca J, White TJ.
    J Manag Care Pharm; 2011 Oct; 17(8):596-609. PubMed ID: 21942301
    [Abstract] [Full Text] [Related]

  • 10. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial.
    Kendler DL, Marin F, Zerbini CAF, Russo LA, Greenspan SL, Zikan V, Bagur A, Malouf-Sierra J, Lakatos P, Fahrleitner-Pammer A, Lespessailles E, Minisola S, Body JJ, Geusens P, Möricke R, López-Romero P.
    Lancet; 2018 Jan 20; 391(10117):230-240. PubMed ID: 29129436
    [Abstract] [Full Text] [Related]

  • 11. Risk of fracture in women treated with monthly oral ibandronate or weekly bisphosphonates: the eValuation of IBandronate Efficacy (VIBE) database fracture study.
    Harris ST, Reginster JY, Harley C, Blumentals WA, Poston SA, Barr CE, Silverman SL.
    Bone; 2009 May 20; 44(5):758-65. PubMed ID: 19168160
    [Abstract] [Full Text] [Related]

  • 12. Effects of once-monthly minodronate versus risedronate in osteoporosis patients with rheumatoid arthritis: a 12-month randomized head-to-head comparison.
    Kumagai K, Harigane K, Kusayama Y, Tezuka T, Choe H, Inaba Y, Saito T.
    Osteoporos Int; 2018 Jul 20; 29(7):1637-1642. PubMed ID: 29574518
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Fracture rates and economic outcomes in patients with osteoporosis prescribed risedronate gastro-resistant versus other oral bisphosphonates: a claims data analysis.
    Thomasius F, Palacios S, Alam A, Boolell M, Vekeman F, Gauthier G.
    Osteoporos Int; 2022 Jan 20; 33(1):217-228. PubMed ID: 34490504
    [Abstract] [Full Text] [Related]

  • 16. Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis.
    Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, Mizunuma H, MOVER Study Group.
    Calcif Tissue Int; 2013 Aug 20; 93(2):137-46. PubMed ID: 23644930
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effects of three oral bisphosphonate therapies on the peripheral skeleton in postmenopausal osteoporosis: the TRIO study.
    Paggiosi MA, Peel N, McCloskey E, Walsh JS, Eastell R.
    Osteoporos Int; 2014 Dec 20; 25(12):2729-41. PubMed ID: 25074351
    [Abstract] [Full Text] [Related]

  • 18. Ibandronate in the Prevention of Vertebral and Nonvertebral Osteoporotic Fractures: A Systematic Review of Experimental and Observational Studies.
    Mendes D, Penedones A, Alves C, Oliveira T, Donato A, Batel-Marques F.
    J Clin Rheumatol; 2023 Mar 01; 29(2):78-83. PubMed ID: 36731043
    [Abstract] [Full Text] [Related]

  • 19. Adherence to and gastrointestinal tolerability of monthly oral or quarterly intravenous ibandronate therapy in women with previous intolerance to oral bisphosphonates: a 12-month, open-label, prospective evaluation.
    Lewiecki EM, Babbitt AM, Piziak VK, Ozturk ZE, Bone HG.
    Clin Ther; 2008 Apr 01; 30(4):605-21. PubMed ID: 18498910
    [Abstract] [Full Text] [Related]

  • 20. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY.
    Clin Ther; 2006 Apr 01; 28(4):475-90. PubMed ID: 16750461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.